BSGM - バイオシグ・テクノロジ―ズ （BioSig Technologies Inc.） バイオシグ・テクノロジ―ズBSGMのチャート
BSGMの企業情報
| symbol | BSGM |
|---|---|
| 会社名 | BioSig Technologies Inc （バイオシグ・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 BioSig Technologies Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company's PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms and helps in making clinical decisions in real-time. It is also developing signal-processing tools which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System. バイオシグ・テクノロジ―ズは米国の医療機器開発企業。生理学的信号から生物医学的信号の情報を抽出するための信号処理技術プラットフォ―ムの開発に従事。電気生理学研究やカテ―テル・アブレ―ション手術の現場で、すばやく正確な臨床判断を下す事を容易にするために開発された「PURE EP」システムが主力製品。本社所在地はカリフォルニア州ロサンゼルス。 BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). |
| 本社所在地 | 12424 Wilshire Blvd. Suite 745 Los Angeles CA 90025 USA |
| 代表者氏名 | Kenneth L. Londoner ケネス・L・ロンドン |
| 代表者役職名 | Executive Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 310-820-8100 |
| 設立年月日 | 39845 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.biosigtech.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bsgm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.38155 |
| 終値（lastsale） | 5.27 |
| 時価総額（marketcap） | 78723033.39 |
| 時価総額 | 時価総額（百万ドル） 77.82676 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 74.72862 |
| 当期純利益 | 当期純利益（百万ドル） -15.40750 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioSig Technologies Inc revenues was not reported. Net loss applicable to common stockholders increased 41% to $9M. Higher net loss reflects General and administrative increase of 88% to $6.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.67 to -$0.68. |
BSGMのテクニカル分析
BSGMのニュース
BioSig''s Signal Processing System for Arrhythmia Care To Be Featured At The Kansas City Heart Rhythm Symposium 2021/08/19 15:00:00 Benzinga
Westport, CT, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM ) ("BioSig" or the "Company"), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would participate in the Kansas City Heart Rhythm Symposium, due to take place on August 21-22, 2021 at the Overland Park Convention Center. The Company''s clinical and commercial teams will host product demonstrations that will showcase the latest clinical data and the newest software features of its PURE EP(tm) System, the non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. The Company''s technology will also be featured in a presentation at the Technology Theater during the Symposium. The presentation titled "PURE EP(tm) - A New Standard in Signal Processing" will be conducted during the sessions beginning at noon on Saturday, August 21, 2021, at the Technology Theatre.
BioSig to Host Conference Call to Unblind Clinical Data Collected with its Signal Processing Technology for Arrhythmia Care 2021/07/12 14:30:00 Intrado Digital Media
Westport, CT, July 12, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EP(tm) 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. Davids Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA.
BioSig Announces Closing of Public Offering of Common Stock 2021/07/07 20:10:00 Intrado Digital Media
Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering were $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig.
Mayo Clinic Purchases BioSig''s PURE EP for use at its Phoenix Location 2021/07/06 13:44:12 Benzinga
According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM ) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP System in April 2021. Under the terms of the commercial transaction, the Foundation is acquiring the PURE EP System for clinical use at Mayo Clinic Phoenix Campus in Arizona. Previously, the institution acquired multiple PURE EP Systems for its Florida and Minnesota Mayo Clinic campuses. To date, more than 1,000 patient cases have been conducted using the PURE EP System by 52 physicians across nine clinical sites. The company is excited about the new sale to the Mayo Clinic and is confident that this denotes the efficacy and potential of its technologies. In fact, its not just the Mayo Clinic Full story available on Benzinga.com
BioSig Announces Closing of Public Offering of Common Stock 2021/07/07 20:10:00 Intrado Digital Media
Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering were $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig.
Mayo Clinic Purchases BioSig''s PURE EP for use at its Phoenix Location 2021/07/06 13:44:12 Benzinga
According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM ) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP System in April 2021. Under the terms of the commercial transaction, the Foundation is acquiring the PURE EP System for clinical use at Mayo Clinic Phoenix Campus in Arizona. Previously, the institution acquired multiple PURE EP Systems for its Florida and Minnesota Mayo Clinic campuses. To date, more than 1,000 patient cases have been conducted using the PURE EP System by 52 physicians across nine clinical sites. The company is excited about the new sale to the Mayo Clinic and is confident that this denotes the efficacy and potential of its technologies. In fact, its not just the Mayo Clinic Full story available on Benzinga.com
Financings for July 2, 2021 2021/07/02 16:00:00 BioWorld
Med-tech firms raising money in public or private financings, including: Biosig Technologies, Nyxoah.
BioSig Technologies Raises $10M Via Equity Issued At $4/Share 2021/07/02 13:37:27 Benzinga
BioSig Technologies Inc (NASDAQ: BSGM ) has priced its previously announced underwritten public offering of 2.5 million shares at $4.00 per share , representing a discount of 8% from the last close price of $4.35 on Thursday. The gross proceeds will be approximately Full story available on Benzinga.com
BioSig Announces Pricing of Public Offering of Common Stock 2021/07/02 12:15:00 Intrado Digital Media
Westport, CT, July 02, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering are expected to be approximately $10 million, or approximately $11.5 million if the underwriter exercises its 30-day option to purchase an additional 15% of the number of shares of common stock offered in the public offering in full, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig. The offering is expected to close on July 7, 2021, subject to the satisfaction of customary closing conditions.
BioSig Technologies under pressure on announcement of common stock public offering 2021/07/01 20:30:13 Seeking Alpha
BioSig Announces Proposed Public Offering of Common Stock 2021/07/01 20:05:00 Intrado Digital Media
Westport, CT, July 01, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it has commenced an underwritten public offering of its common stock. BioSig also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Proactive news headlines including BioSig Technologies, Mirasol Resources, Canada Silver Cobalt Works and Versus Systems 2021/06/30 18:10:00 Intrado Digital Media
New York , June 30, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:
BioSig Completes 1,000 Patient Cases and Expects 1,500 more at the end of 2021 2021/06/30 17:36:44 Benzinga
According to recent reports , the global electroceuticals/bioelectric medicine market is currently worth $16.8 billion and is projected to reach $21.5 billion by 2026, at a compound annual growth rate (CAGR) of 5.0% BioSig Technologies, Inc. (NASDAQ: BSGM ), a medical technology company, unlocks the future of bioelectronic medicine with its PURE EP System. The company recently increased its procedural volume targets to 15,000 due to accelerated technology usage, after delivering 425 procedures at the end of 2020. Today it announced physicians completed 1,000 patient cases. We are thrilled to cross the 1,000-case milestone, a figure that was our initial target for the entire 2021, said Kenneth L. Londoner, chairman and CEO of BioSig Technologies. Most importantly, this case Full story available on Benzinga.com
BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology - Stocks News Feed 2021/06/30 14:03:32 Stocks News Feed
The Company recently increased its procedural volume targets due to accelerated technology usage BioSig expands its commercial team to target technology adoption across three strategic regions Westport, CT, June 30, 2021 /GLOBE NEWSWIRE/ BioSig Technologies, Inc. (NASDAQ: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to Read More »BioSig Completes 1000 Patient Cases with its Signal Processing System for Electrophysiology